Recruiting

Observational Study

Sponsor:

Genespire Srl

Code:

NCT07432880

Conditions

Methylmalonic Acidemia (MMA)

Eligibility Criteria

Sex: All

Age: 0 - 16

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Methylmalonic Acidemia (MMA) is a severe and rare condition that affects how the body turns food into energy. In people with MMA, the body is missing or has a very low activity of a specific protein (an enzyme called methylmalonyl-CoA mutase (MMUT)) needed to break down certain proteins and fats in everyday food. Because this process does not work properly, a harmful substance called methylmalonic acid builds up in the blood and tissues, causing damage in the body.

Most people with MMA have an altered MMUT gene, which affects the enzyme methylmalonyl-CoA mutase. MMA often appears in infancy or early childhood, but some people are diagnosed later.

MMA affects approximately 1 in every 100,000 babies born and primarily impacts the liver, brain and kidneys. MMA poses significant challenges as it can result in complications such as dangerous acid levels in the blood, problems with the brain and nerves, visions problems, problems with how the pancreas, liver, and the kidneys work, as well as growth and development delays.

The main purpose of this observational study that tracks how the disease develops over time is to gather necessary data and evidence to confirm which signs in the body and blood test results can reliably show disease activity related to MMA. These confirmed signs and blood test results will be used for future research into developing new treatments for MMA. The data will be collected from participants with severe symptoms with and without liver transplant.

Conditions

Methylmalonic Acidemia (MMA)

Study ID

NCT07432880

Start date

Aug 13, 2026

Status verified date

Nov, 2026

Completion date

Aug, 2030

Anticipated

Primary completion date

Aug, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 16

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Aged ≤16 years at screening visit
2. With or without previous liver (or combined liver/kidney) transplantation at time of screening (note: number of transplanted participants capped at n=15) 3. Confirmed laboratory diagnosis of Isolated MMA caused by mutations in the MMUT gene (NOTE: if a historical genetic mutational analysis report was available at Screening visit but was not from a CLIA/ISO15189 approved laboratory, a confirmatory sample will be taken during the study. However the original lab report will be adequate for study eligibility consideration)..

4\. Severe MMA phenotype.

  • For untransplanted participants, all of the following criteria (a-c) must be met to qualify as "severe" MMA phenotype:

1. Serum methylmalonic acid (sMMA) level of >100 µmol/L at the Screening visit
2. An unscheduled ER visit, hospitalization or requirement for use of the sick day diet regimen in the 12 months prior to the screening visit
3. Considered to potentially require future liver transplantation to improve metabolic stability in accordance with MMA transplantation guidelines (Baumgartner 2014, Forny 2021, Sen 2023)
  • For participants with previous liver or combined liver and kidney transplantation, the phenotype of the participant will be judged by the Investigator to be severe if both of the following were applicable prior to transplantation:

1. Pre-transplant serum methylmalonic acid (sMMA) level of >100 µmol/L AND
2. Transplantation was conducted to improve metabolic stability in accordance with MMA transplantation guidelines (Baumgartner 2014, Forny 2021, Sen 2023).

NOTE: sMMA pre-transplant measure must have been obtained within 6 months prior to transplant. An alternative blood MMA concentration may be used (e.g. plasma MMA, or dry blood spot), if sMMA is unavailable. Details of the assay used must be provided and additional samples will be collected during the study to allow comparison to sMMA results.

Exclusion Criteria:

1. Participant/parent/legal guardian/caregiver not willing to consent to participate
2. Current participation in another interventional or therapeutic study
3. Prior participation in a gene therapy clinical trial including mRNA therapy
4. Participants who, in the opinion of the Site Investigator, would be unable or unsuitable to participate in the demands of the study, for example but not limited to participants unable to travel to protocol study visits or participants under palliative care.
5. For participants who are post-liver transplant only, participant will be excluded if no prior pre-liver transplant measurements of blood MMA are available.

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Unstransplanted severe MMA

without previous liver (or combined liver/kidney) transplantation at time of screening

Transplanted severe MMA

with previous liver (or combined liver/kidney) transplantation at time of screening

Primary outcome measure

  • Evaluation of disease progression using biochemical biomarkers [ Time Frame: Baseline, Month 6, Month 12, Month 18, Month 24, Month 30 and Month 36 ]

Central Contacts and Locations

Central contacts

Locations

CHOP (Children's hospital of Philadelphia)

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Can Ficicioglu, PhD

ficicioglu@chop.edu

Principal Investigator:

can Ficicioglu, PhD

More Information

Sponsor

Genespire Srl

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • MMA, MCA, observational, MUT, MMUT,

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Genespire Srl on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.